Navigation Links
RXi Pharmaceuticals Announces Application for NASDAQ Capital Market Listing and Reverse Stock Split
Date:7/22/2013

WESTBOROUGH, Mass., July 22, 2013 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it has filed an application for listing on The NASDAQ Capital Market.

In addition to the application for listing on The NASDAQ Capital Market, RXi today announced a 1-for-30 reverse split of its issued and outstanding shares of common stock. Trading will begin on a post-split basis at the open of the OTCQX on July 24, 2013 under new CUSIP number 74979C303. No fractional shares of common stock will be issued as a result of the reverse stock split and instead holders will receive cash in lieu of fractional shares to which they would otherwise be entitled.

"This reverse stock split combined with a possible NASDAQ Capital Market Listing is the next important step for RXi Pharmaceuticals in becoming a strong biotechnology company," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that ''If approved, we believe that the NASDAQ listing and the reverse stock split will create the conditions for RXi to gain access to a broader institutional investment community, to strengthen our financing flexibility, and to provide greater liquidity for our shareholders."

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTCQX: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great  promise because of their ability to down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012.  For more information, please visit www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, including future expectations regarding our NASDAQ listing, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks that NASDAQ may determine that we do not meet their initial listing criteria, that if the listing is approved it will not have the intended effects of improving access to certain investors, financing flexibility and liquidity; risks that RXi may not be able to successfully develop its candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

 


'/>"/>
SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2020)... (PRWEB) , ... March 03, 2020 , ... ... serving the pharmaceutical, biotech and medical device industries, was recognized by INC. 5,000 ... puts forward annual lists to note industry leaders greatly impacting their spheres of ...
(Date:2/28/2020)... DIEGO (PRWEB) , ... February 26, 2020 , ... ... HS7 system combines a high-speed camera with a dedicated controller, thus simplifying ... frames per second, the HS7 is the first of Fastec Imaging’s new HS ...
(Date:2/21/2020)... ... February 20, 2020 , ... ... to perform complex, efficient and elegant chemistry. Humans have been increasingly successful ... own goals. , Through rapidly evolving technologies and strategies for modern molecular ...
(Date:2/21/2020)... ... February 21, 2020 , ... Pharmaceutical manufacturers are under increasing ... adapt to new approaches like ‘Industry 4.0’ and continuous manufacturing, combat the growing ... and therapies. But with an industry with the world’s tightest regulations and complex ...
Breaking Biology Technology:
(Date:3/3/2020)... ... March 03, 2020 , ... Amplify Surgical, Inc., today announces that ... Interbody Fusion System. , The landmark case was performed by Dr. Ali ... Dr. Najafi noted, “dualX has completely changed the game for expandable interbodies. The ...
(Date:3/2/2020)... ... ... Nominations are now being accepted for the 2020 Women in Biometrics ... and SecureIDNews and co-presented with sponsors IDEMIA , Biometric Update ... year’s Women in Biometrics Awards will be honored at the 2020 SIA GovSummit, held ...
(Date:2/28/2020)... ... February 27, 2020 , ... An upcoming episode ... solutions for maladies, such as Inflammatory Bowel Disease (IBD), specifically Crohn’s Disease (Crohn’s), ... focus on a novel platform developed by Deka Biosciences, Inc. (Deka Biosciences), that ...
Breaking Biology News(10 mins):